Reviva Pharmaceuticals Stock (NASDAQ: RVPH)

Reviva Pharmaceuticals

REVIVA PHARMACEUTICALS HOLDI

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

London,,Uk,-,March,2021:,Spotify,Music,And,Audio,Streaming

News

Price Target

Markets

Analyst Ratings

Trading Ideas

OLLI

RVPH

SPOT

URBN

Spotify To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday

UltaBeautyGreenwood,,Indiana, - ,United,States,-,June,16,2020:,Beauty

Pre-Market Outlook

FWRG

PCVX

PHGE

TVTX

ULTA

Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday

Amazon, Crowdstrike, Autodesk, Dell, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Movers

CANG

CELC

DBGI

EVGO

GRYP

LAES

MAMA

MITK

Merrill Lynch & Strategic Return Notes for Select 10 Index

NAYA

OPTX

PSBD

PTPI

SEDG

SIDU

TNXP

WBUY

Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings, Inc. - Warrants

Press Releases

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Health Care

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Earnings

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

Reviva to Participate in the Citizens Life Sciences Conference

Reviva to Participate in the A.G.P. Healthcare Company Showcase

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Participate in Upcoming Investor Conferences in May 2025

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Assertio Holdings

CalciMedica

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

IGC Pharma

Ikena Oncology

Iterum Therapeutics

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

NRX Pharmaceuticals

Nutriband

Pulmatrix

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Scilex Holding

SCYNEXIS

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Veru

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

D. Boral Capital

HC Wainwright & Co.

Maxim Group

Roth MKM

EF Hutton

Comments

Reviva Pharmaceuticals

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell